Wells Fargo
EGRX

Wells Fargo’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Wells Fargo’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-351
Closed -$1.97K – 7121
2024
Q2 		$1.97K Sell
351
-3,656
-91% -$15.9K ﹤0.01% 6019
2024
Q1 		$21K Buy
4,007
+772
+24% +$4.24K ﹤0.01% 5565
2023
Q4 		$16.9K Buy
3,235
+590
+22% +$5.83K ﹤0.01% 5694
2023
Q3 		$41.7K Sell
2,645
-1,384
-34% -$24.9K ﹤0.01% 5271
2023
Q2 		$78.3K Buy
4,029
+1,299
+48% +$30.8K ﹤0.01% 5182
2023
Q1 		$77.5K Buy
2,730
+2,246
+464% +$66.7K ﹤0.01% 4947
2022
Q4 		$14.1K Sell
484
-658
-58% -$20.9K ﹤0.01% 5411
2022
Q3 		$31K Buy
1,142
+43
+4% +$1.58K ﹤0.01% 5179
2022
Q2 		$48K Sell
1,099
-40,960
-97% -$1.88M ﹤0.01% 5044
2022
Q1 		$2.08M Sell
42,059
-1,996
-5% -$95.8K ﹤0.01% 3253
2021
Q4 		$2.24M Sell
44,055
-219,766
-83% -$11.4M ﹤0.01% 3385
2021
Q3 		$14.7M Buy
263,821
+90,056
+52% +$4.43M ﹤0.01% 1895
2021
Q2 		$7.44M Buy
173,765
+120,473
+226% +$4.97M ﹤0.01% 2487
2021
Q1 		$2.22M Buy
53,292
+7,997
+18% +$371K ﹤0.01% 3597
2020
Q4 		$2.11M Buy
45,295
+11,266
+33% +$527K ﹤0.01% 3459
2020
Q3 		$1.45M Buy
34,029
+318
+0.9% +$13.9K ﹤0.01% 3576
2020
Q2 		$1.62M Buy
33,711
+1,587
+5% +$79.2K ﹤0.01% 3428
2020
Q1 		$1.48M Sell
32,124
-2,611
-8% -$131K ﹤0.01% 3253
2019
Q4 		$2.09M Buy
34,735
+679
+2% +$40.5K ﹤0.01% 3316
2019
Q3 		$1.93M Buy
34,056
+5,646
+20% +$318K ﹤0.01% 3362
2019
Q2 		$1.58M Buy
28,410
+3,480
+14% +$182K ﹤0.01% 3533
2019
Q1 		$1.26M Buy
24,930
+2,065
+9% +$91.9K ﹤0.01% 3711
2018
Q4 		$920K Buy
22,865
+3,526
+18% +$182K ﹤0.01% 3898
2018
Q3 		$1.34M Sell
19,339
-3,550
-16% -$269K ﹤0.01% 3738
2018
Q2 		$1.73M Sell
22,889
-398
-2% -$25K ﹤0.01% 3567
2018
Q1 		$1.23M Buy
23,287
+2,936
+14% +$171K ﹤0.01% 3754
2017
Q4 		$1.09M Sell
20,351
-1,155
-5% -$64.3K ﹤0.01% 3873
2017
Q3 		$1.28M Buy
21,506
+5,640
+36% +$341K ﹤0.01% 3661
2017
Q2 		$1.25M Buy
15,866
+2,663
+20% +$218K ﹤0.01% 3561
2017
Q1 		$1.09M Sell
13,203
-4,338
-25% -$323K ﹤0.01% 3680
2016
Q4 		$1.39M Buy
17,541
+11,166
+175% +$811K ﹤0.01% 3445
2016
Q3 		$446K Buy
6,375
+2,707
+74% +$150K ﹤0.01% 4017
2016
Q2 		$143K Buy
3,668
+94
+3% +$3.91K ﹤0.01% 4605
2016
Q1 		$145K Sell
3,574
-6,414
-64% -$407K ﹤0.01% 4605
2015
Q4 		$885K Sell
9,988
-8,641
-46% -$682K ﹤0.01% 3551
2015
Q3 		$1.38M Buy
18,629
+15,794
+557% +$1.31M ﹤0.01% 3271
2015
Q2 		$229K Sell
2,835
-1,017
-26% -$66.2K ﹤0.01% 4544
2015
Q1 		$161K Sell
3,852
-4,557
-54% -$129K ﹤0.01% 4525
2014
Q4 		$130K Buy
+8,409
New +$107K ﹤0.01% 4640
2014
Q3 		– Sell
-500
Closed -$7K – 6387
2014
Q2 		$7K Sell
500
-300
-38% -$3.42K ﹤0.01% 5739
2014
Q1 		$10K Buy
+800
New +$10.9K ﹤0.01% 5404

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wells Fargo's EGRX Position: Q3 2024 in Review

Wells Fargo sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 351 shares — an estimated $1.97K sold.

Wells Fargo first reported a position in EGRX in Q1 2014 and held it in 41 quarters. The position peaked at $14.7M in Q3 2021. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • Wells Fargo reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • Wells Fargo sold 351 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $1.97K.
  • Wells Fargo first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 41 quarters.
  • Wells Fargo's Eagle Pharmaceuticals, Inc. position peaked at $14.7M in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.